Blue-blocking Glasses for Sleep Disorders in Child and Adolescent Psychiatry

Summary

Sleep problems and regulation difficulties are frequent in the child and adolescent psychiatry population. Insomnia and delayed sleep-wake phase disorders (DSPWD) are highly prevalent, and risk factors for developing more severe illness courses and chronic disorders. Pharmacological treatments of sleep disorders dominate even for the youngest patients but are unsupported by long-term data on outcome and side effects. The majority of non-pharmacological treatment options are composite and resource demanding. The investigators will examine the effects and feasibility of the isolated intervention of evening/night use of blue-blocking glasses/real darkness as adjunctive treatment for insomnia and delayed sleep phase disorder in inpatient and outpatient settings for children and adolecents.

Conditions

• Insomnia
• Delayed Sleep Phase Disorder
• Hyperarousal
• Transdiagnostic Psychopathology
• Child and Adolescent Psychiatry

Interventions

DEVICE

Blue-blocking glasses (BB-glasses) or real darkness from 9 p.m. to desired wake-up time + night mode setting on mobile phone

Blue-blocking glasses and night mode on mobile phoneBlue-blocking glasses (BB-glasses) or real darkness from 9 p.m. to desired wake-up time + application of dark mode setting on the participant's mobile phone (if not already in use) + registration of brightness on participant's mobile phone screen (%) + treatment as usual

OTHER

Control

Application of dark mode setting on the participant's mobile phone (if not already in use) + registration of brightness on particpants's mobile phone screen (%) + Treatment as usual

Sponsors & Collaborators

• University of Bergen

  collaborator OTHER

• University of Oslo

  collaborator OTHER

• University Hospital of North Norway

  collaborator OTHER

• Helse Vest

  collaborator OTHER

• Helse Fonna

  lead OTHER

Principal Investigators

• Tone Elise G Henriksen, MD PhD · Helse Fonna

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

12 Years

Max Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-02-01

Primary Completion

2027-06-01

Completion

2027-06-01

Countries

• Norway

Study Locations